カテゴリ： GlobalData, カナダ, 企業調査

ProMIS Neurosciences Inc (PMN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：ProMIS Neurosciences Inc (PMN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9818
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：82
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：カナダ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
ProMIS Neurosciences Inc (ProMIS), formerly Amorfix Life Sciences Ltd is a development stage biopharmaceutical company which focuses on the development of therapeutic antibodies and diagnostics for the treatment of misfolded protein diseases. The company uses ProMIS technology, helps in predicting new disease specific epitopes on the molecular surface of misfolded proteins. Based on ProMIS technology, the company is developing antibody therapeutics and diagnostics targeting cancer and amyotrophic lateral sclerosis (ALS). It’s products and services include therapeutics, diagnostic kits, diagnostic services, and reagents. ProMIS is headquartered in Toronto, Ontario, Canada.

ProMIS Neurosciences Inc (PMN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ProMIS Neurosciences Inc, Medical Devices Deals, 2012 to YTD 2018 10
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Amorfix Life Sciences Acquires Superoxide Dismutase-1 Technology From Dr. Neil Cashman 13
Partnerships 14
Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 14
Amorfix Life Sciences Enters Into Co-Development Agreement With Trellis Bioscience 15
Amorfix Life Sciences Enters Into Agreement With Cangene To Develop Therapeutic Antibodies For Oncology 16
Equity Offering 17
ProMIS Neurosciences Raises USD5.6 Million in Private Placement of Shares and Warrants 17
ProMIS Neurosciences Raises USD1 Million in Second Tranche of Private Placement of Units 18
ProMIS Neurosciences Raises USD1.8 Million in First Tranche of Private Placement of Shares 20
ProMIS Neurosciences Raises USD0.4 Million in Private Placement of Units 21
ProMIS Neurosciences Raises USD0.8 Million in Private Placement of Units 22
ProMIS Neurosciences Raises USD0.3 Million in Second and Final Tranche of Private Placement of Shares 23
ProMIS Neurosciences Raises USD0.5 Million in First Tranche of Private Placement of Shares 24
ProMIS Neurosciences to Raise Funds Through Rights Offering of Shares 25
ProMIS Neurosciences Raises USD0.77 million in Second and Final Tranche of Private Placement of Shares 26
Amorfix Life Sciences Raises USD1.2 Million in First Tranche of Private Placement of Shares 27
Amorfix Life Sciences Raises USD0.31 Million in Private Placement of Shares and Warrants 28
Amorfix Life Sciences Completes Third Tranche Of Private Placement Of Shares And Warrants For US$1 Million 29
Amorfix Life Sciences Completes Private Placement Of Securities For US$0.4 Million 30
Amorfix Life Sciences Completes Private Placement Of Units For US$0.5 Million 31
Amorfix Life Sciences Raises USD0.25 Million In a Private Placement Of Shares 32
Amorfix Life Sciences Completes Second Tranche Of Private Placement Of Shares For US$0.2 Million 33
Amorfix Life Sciences Completes First Tranche Of Private Placement Of Units For US$0.5 Million 34
Amorfix Life Sciences Completes Second And Final Tranche Of Private Placement Of Units For US$0.3 Million 35
Amorfix Life Sciences Completes Private Placement Of Units For US$0.2 Million 36
Amorfix Life Sciences Completes Private Placement Of Units For US$1 Million 37
Amorfix Life Sciences Completes Second Tranche Of Private Placement Of Units For US$0.08 Million 38
Asset Transactions 40
Amorfix Life Sciences Plans to Divest its Assets 40
ProMIS Neurosciences Inc – Key Competitors 41
ProMIS Neurosciences Inc – Key Employees 42
ProMIS Neurosciences Inc – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 44
Financial Announcements 44
Aug 14, 2018: Promis Neurosciences reports second quarter 2018 financial results 44
May 11, 2018: ProMIS Neurosciences Announces First Quarter 2018 Results 46
Mar 14, 2018: ProMIS Neurosciences Announces Fiscal Year 2017 Annual Results 48
Nov 13, 2017: ProMIS Neurosciences Announces Third Quarter 2017 Results 50
Aug 11, 2017: ProMIS Neurosciences Announces Second Quarter 2017 Results 52
Jul 10, 2017: ProMIS Neurosciences Provides Second Quarter Update for 2017 54
May 09, 2017: ProMIS Neurosciences Announces Q1 2017 Quarterly Results 55
Mar 30, 2017: ProMIS Neurosciences announces overview of first quarter 2017 progress and outlook for near term value creation 56
Mar 15, 2017: ProMIS Neurosciences Announces Fiscal 2016 Annual Results 57
Corporate Communications 59
Sep 13, 2018: ProMIS Neurosciences appoints James Kupiec, MD as Chief Medical Officer 59
Dec 04, 2017: ProMIS Neurosciences Announces Trading on OTCQB Venture Market 60
Jun 06, 2017: ProMIS Neurosciences Appoints William C. Mobley to Scientific Advisory Board 61
Mar 22, 2017: ProMIS Neurosciences Announces Appointment of Daniel Geffken as Chief Financial Officer 62
Mar 02, 2017: ProMIS Neurosciences announces appointment of Anthony Giovinazzo to its Board of Directors 63
Government and Public Interest 64
May 31, 2017: ProMIS Neurosciences Identifies Novel Therapeutic Epitope Target for ALS and Dementia 64
Product News 65
10/11/2018: ProMIS Neurosciences identifies novel antibody drug candidates for Parkinsons Disease 65
09/28/2017: ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference 66
09/19/2017: ProMIS Neurosciences Announces Successful Humanization of Lead Product Candidate PMN310 for Alzheimer’s Disease 67
09/13/2017: ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer’s Disease 68
07/19/2017: ProMIS Neurosciences Presents at AAIC 2017 Data from Alzheimer’s Disease Program 69
07/06/2017: ProMIS Neurosciences’ Sponsored Research Agreement with University of British Columbia Receives Matching Grant from Canadian Institutes of Health Research 70
06/26/2018: ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases 71
05/24/2017: ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer’s Disease 72
Apr 10, 2018: ProMIS Neurosciences Announces Publication of Peer Reviewed Scientific Paper Describing a Novel Target on Toxic Oligomers of Amyloid Beta in Alzheimer’s Disease 73
03/28/2017: ProMIS Neurosciences announces presentation and expert panel participation at the Neuroscience Biopartnering and Investment Forum 74
01/05/2017: ProMIS Neurosciences declares PMN 310 its first lead product for development in Alzheimer’s disease 75
Clinical Trials 76
Jan 23, 2018: ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies 76
Jan 04, 2018: ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies 77
Oct 17, 2017: ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer’s Disease 78
Jul 05, 2017: ProMIS Neurosciences to Present Preclinical Data from Alzheimer’s Disease Program at AAIC 2017 79
Other Significant Developments 80
Aug 29, 2018: ProMIS Neurosciences Issues Narrated Overview of Second Quarter 2018 Results 80
Oct 11, 2017: ProMIS Neurosciences Provides Third Quarter Update for 2017 81
Appendix 82
Methodology 82
About GlobalData 82
Contact Us 82
Disclaimer 82

List of Tables
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ProMIS Neurosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ProMIS Neurosciences Inc, Medical Devices Deals, 2012 to YTD 2018 10
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Amorfix Life Sciences Acquires Superoxide Dismutase-1 Technology From Dr. Neil Cashman 13
Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences 14
Amorfix Life Sciences Enters Into Co-Development Agreement With Trellis Bioscience 15
Amorfix Life Sciences Enters Into Agreement With Cangene To Develop Therapeutic Antibodies For Oncology 16
ProMIS Neurosciences Raises USD5.6 Million in Private Placement of Shares and Warrants 17
ProMIS Neurosciences Raises USD1 Million in Second Tranche of Private Placement of Units 18
ProMIS Neurosciences Raises USD1.8 Million in First Tranche of Private Placement of Shares 20
ProMIS Neurosciences Raises USD0.4 Million in Private Placement of Units 21
ProMIS Neurosciences Raises USD0.8 Million in Private Placement of Units 22
ProMIS Neurosciences Raises USD0.3 Million in Second and Final Tranche of Private Placement of Shares 23
ProMIS Neurosciences Raises USD0.5 Million in First Tranche of Private Placement of Shares 24
ProMIS Neurosciences to Raise Funds Through Rights Offering of Shares 25
ProMIS Neurosciences Raises USD0.77 million in Second and Final Tranche of Private Placement of Shares 26
Amorfix Life Sciences Raises USD1.2 Million in First Tranche of Private Placement of Shares 27
Amorfix Life Sciences Raises USD0.31 Million in Private Placement of Shares and Warrants 28
Amorfix Life Sciences Completes Third Tranche Of Private Placement Of Shares And Warrants For US$1 Million 29
Amorfix Life Sciences Completes Private Placement Of Securities For US$0.4 Million 30
Amorfix Life Sciences Completes Private Placement Of Units For US$0.5 Million 31
Amorfix Life Sciences Raises USD0.25 Million In a Private Placement Of Shares 32
Amorfix Life Sciences Completes Second Tranche Of Private Placement Of Shares For US$0.2 Million 33
Amorfix Life Sciences Completes First Tranche Of Private Placement Of Units For US$0.5 Million 34
Amorfix Life Sciences Completes Second And Final Tranche Of Private Placement Of Units For US$0.3 Million 35
Amorfix Life Sciences Completes Private Placement Of Units For US$0.2 Million 36
Amorfix Life Sciences Completes Private Placement Of Units For US$1 Million 37
Amorfix Life Sciences Completes Second Tranche Of Private Placement Of Units For US$0.08 Million 38
Amorfix Life Sciences Plans to Divest its Assets 40
ProMIS Neurosciences Inc, Key Competitors 41
ProMIS Neurosciences Inc, Key Employees 42
ProMIS Neurosciences Inc, Subsidiaries 43

List of Figures
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ProMIS Neurosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ProMIS Neurosciences Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[ProMIS Neurosciences Inc (PMN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Anheuser-Busch InBev NVSA (ABI)：企業の財務・戦略的SWOT分析
    Anheuser-Busch InBev NVSA (ABI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • UNITIKA LTD.：企業の戦略・SWOT・財務情報
    UNITIKA LTD. - Strategy, SWOT and Corporate Finance Report Summary UNITIKA LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Petoro AS：石油・ガス：M&Aディール及び事業提携情報
    Summary Petoro AS (Petoro) is an oil and gas asset management company. The company manages Norwegian state’s direct financial interests (SDFI) in Norwegian Continental Shelf (NCS) oil and gas assets. It has the responsibility for and to attend to the commercial aspects related to the state's direct …
  • University of New Mexico：製薬・医療：M&Aディール及び事業提携情報
    Summary University of New Mexico (UNM) is an educational service provider that offers bachelors, masters, doctoral and professional degree programs in various fields. The university offers programs such as evening and weekend degree programs, continuing education, extended learning, Latin American s …
  • Humanigen Inc (HGEN)：製薬・医療：M&Aディール及び事業提携情報
    Summary Humanigen Inc (Humanigen), formerly KaloBios Pharmaceuticals Inc is a biopharmaceutical company that develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company provides Ifabotuzumab(anti-EphA3) and Lenzilumab(anti-GM-CSF) recombinant monoclonal antibodi …
  • SGL Carbon SE (SGL)：企業の財務・戦略的SWOT分析
    SGL Carbon SE (SGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Akamai Technologies Inc (AKAM)：企業の財務・戦略的SWOT分析
    Akamai Technologies Inc (AKAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Carmell Therapeutics Corp：製品パイプライン分析
    Summary Carmell Therapeutics Corp (Carmell) is a biotechnology company that develops and commercializes bone healing accelerants and tissue healing accelerants. Its pipeline portfolio encompasses adjunctive treatment for long bone fractures in Phase I and Phase II a; and adjunctive treatment for tot …
  • Callaway Golf Company (ELY)：企業の財務・戦略的SWOT分析
    Callaway Golf Company (ELY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Bone Solutions Inc：医療機器：M&Aディール及び事業提携情報
    Summary Bone Solutions Inc (BSI) is a medical device company that provides orthobiologics technology solutions. The company also develops magnesium oxide based technologies for multitude of orthopedic applications. It provides osteocrete bone graft substitute that offers adhere ligaments and tendons …
  • Alibaba Group Holding Limited：企業の戦略・SWOT・財務情報
    Alibaba Group Holding Limited - Strategy, SWOT and Corporate Finance Report Summary Alibaba Group Holding Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Compagnie Plastic Omnium SA (POM)：企業の財務・戦略的SWOT分析
    Compagnie Plastic Omnium SA (POM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Inotek Pharmaceuticals Corp (RCKT)：製薬・医療：M&Aディール及び事業提携情報
    Summary Inotek Pharmaceuticals Corp (IPC) is a clinical-stage biopharmaceutical company that focus on the discovery and development of novel therapeutics for the treatment of glaucoma and serious diseases of the eye. The company’s trabodenoson is a selective adenosine mimetic that stimulates a speci …
  • Repower AG：電力：M&Aディール及び事業提携情報
    Summary Repower AG (Repower), formerly Ratia Energie AG is an energy company that produces, transmits and distributes electricity. The company's services include trading, market access, and sales support services. It generates electric energy from hydropower, wind power plants, and combined-cycle ga …
  • Sterling Bank Plc：企業の戦略・SWOT・財務分析
    Sterling Bank Plc - Strategy, SWOT and Corporate Finance Report Summary Sterling Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Astra Microwave Products Limited：企業の戦略・SWOT・財務分析
    Astra Microwave Products Limited - Strategy, SWOT and Corporate Finance Report Summary Astra Microwave Products Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Sophia Genetics SA：医療機器：M&Aディール及び事業提携情報
    Summary Sophia Genetics SA (Sophia Genetics) is a health tech company that provides technological solutions such as SOPHiA Artificial Intelligence for clinical genomics and next generation sequencing (NGS) data analysis. The company also provides dry lab, bundle solution, and integrated diagnostic s …
  • Baoding Lightway Green Energy Technology Co Ltd：企業の戦略的SWOT分析
    Baoding Lightway Green Energy Technology Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competito …
  • Covance Inc：企業の戦略的SWOT分析
    Covance Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Massilly Holding S.A.：企業の戦略・SWOT・財務分析
    Massilly Holding S.A. - Strategy, SWOT and Corporate Finance Report Summary Massilly Holding S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆